| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Antonio D'Errico, Rosarita Nasso, Antimo Di Maro, Nicola Landi, Angela Chambery, Rosita Russo, Stefania D'Angelo, Mariorosario Masullo, Rosaria Arcon. Identification and Characterization of Neuroprotective Properties of Thaumatin-like Protein 1a from Nutrients. vol 16. issue 2. 2024-01-26. PMID:38276545. |
identification and characterization of neuroprotective properties of thaumatin-like protein 1a from alzheimer's disease (ad) and parkinson's disease (pd) are multifactorial neurodegenerative disorders that are mostly treated with drugs inhibiting key enzymes of cholinergic and aminergic neurotransmission, such as acetyl and butyryl cholinesterase (ache, buche) or monoamine oxidases (mao)-a/b, and of a |
2024-01-26 |
2024-01-28 |
Not clear |
| Saira Asghar, Nousheen Mushtaq, Ahsaan Ahmed, Laila Anwar, Rabya Munawar, Shamim Akhta. Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer's Disease: AChE, MAO-B, and COX-2 as Molecular Targets. Molecules (Basel, Switzerland). vol 29. issue 2. 2024-01-26. PMID:38276568. |
potential of tryptamine derivatives as multi-target directed ligands for alzheimer's disease: ache, mao-b, and cox-2 as molecular targets. |
2024-01-26 |
2024-01-28 |
Not clear |
| Ashwaq H Bataw. The International journal of neuroscience. vol 134. issue 1. 2024-01-16. PMID:35634646. |
alzheimer's disease (ad) appears as a result of an increase in the accumulation of amyloid beta peptide (aβ) and a decrease in neurotransmitters (acetylcholine) within the brain cells which may be due to increase in acetylcholinesterase (ache) activity and change in expression of apolipoprotein e4 (apoe4) and clusterin (clu) genes. |
2024-01-16 |
2024-01-19 |
Not clear |
| Kunal Bhattacharya, Atanu Bhattacharjee, Manodeep Chakrabort. Assessing the potential of Journal of biomolecular structure & dynamics. 2024-01-11. PMID:38205777. |
assessing the potential of acetylcholinesterase (ache) inhibitors play a crucial role in the treatment of alzheimer's disease. |
2024-01-11 |
2024-01-13 |
Not clear |
| Shoaib Manzoor, Moustafa T Gabr, Mohamed S Nafie, Md Kausar Raza, Ashma Khan, Shahid M Nayeem, Reem K Arafa, Nasimul Hod. Discovery of Quinolinone Hybrids as Dual Inhibitors of Acetylcholinesterase and Aβ Aggregation for Alzheimer's Disease Therapy. ACS chemical neuroscience. 2023-12-27. PMID:38149821. |
we report herein new quinolinone hybrids as dual inhibitors of acetylcholinesterase (ache) and aβ aggregation that function as multitargeted ligands for alzheimer's disease. |
2023-12-27 |
2023-12-29 |
Not clear |
| Bing Zhang, Yu Wang, Donghui Wu, Qilin Zhao, Yaoyao Chen, Yushu Li, Jian Sun, Xiurong Yan. Fluorescent assay for acetylcholinesterase activity and inhibitor screening based on lanthanide organic/inorganic hybrid materials. Analytical methods : advancing methods and applications. 2023-12-20. PMID:38116865. |
it is of great significance for the clinical diagnosis of alzheimer's disease (ad) to achieve the on-site activity evaluation of acetylcholinesterase (ache), the hydrolase of acetylcholine (ach). |
2023-12-20 |
2023-12-23 |
Not clear |
| Pavani K, D S N B K Prasanth, Murthy K R Shadakshara, Sheikh F Ahmad, Ramanjaneyulu Seemaladinne, Mithun Rudrapal, Praveen Kumar Pasal. Citronellal as a Promising Candidate for Alzheimer's Disease Treatment: A Comprehensive Study on In Silico and In Vivo Anti-Acetylcholine Esterase Activity. Metabolites. vol 13. issue 11. 2023-11-25. PMID:37999229. |
one of the primary therapeutic approaches for managing alzheimer's disease (ad) involves the modulation of acetylcholine esterase (ache) activity to elevate acetylcholine (ach) levels inside the brain. |
2023-11-25 |
2023-11-28 |
mouse |
| Saira Naseem, Samra Khan, Safdar Hussain, Muhammad Usman Mirza, Muhammad Ashraf, Zahid Shafiq, John F Tran. Synthesis, biological evaluation, and molecular docking study of xanthene-linked thiosemicarbazones as cholinesterase inhibitors. Journal of biomolecular structure & dynamics. 2023-11-10. PMID:37948312. |
this study delineates the design and synthesis of a series of xanthene-based thiosemicarbazones that show low μm inhibition of acetylcholinesterase (ache) and butyrylcholinesterase (bche), crucial enzymes associated with, among others, alzheimer's disease (ad) pathology. |
2023-11-10 |
2023-11-20 |
Not clear |
| Pooja Khairnar, Ajit Singh, Kailash Ahirwar, Rahul Shukl. ApoE3 Anchored Liposomal Delivery of Rivastigmine for Brain Delivery: Formulation, Characterization, and In Vivo Pharmacokinetic Evaluation. AAPS PharmSciTech. vol 24. issue 8. 2023-11-09. PMID:37945928. |
rivastigmine hydrogen tartrate (rht) is an acetylcholinesterase (ache) inhibitor used in the management of alzheimer's disease (ad). |
2023-11-09 |
2023-11-20 |
Not clear |
| Xia Mu, Shengwei Yuan, Dinglin Zhang, Rui Lai, Chenyi Liao, Guohui L. Selective modulation of alkali metal ions on acetylcholinesterase. Physical chemistry chemical physics : PCCP. 2023-11-07. PMID:37934509. |
acetylcholinesterase (ache) is an important hydrolase in cholinergic synapses and a candidate target in the treatment of alzheimer's disease. |
2023-11-07 |
2023-11-08 |
human |
| Sukriti Srivastava, Shilpa Sharma, Shashank Deep, Sunil Kumar Khar. Screening of Multitarget-Directed Natural Compounds as Drug Candidates for Alzheimer's Disease Using ACS omega. vol 8. issue 41. 2023-10-24. PMID:37867692. |
indeed, the major available commercial drugs (donepezil, rivastigmine, and galantamine) against alzheimer's are ache inhibitors. |
2023-10-24 |
2023-11-08 |
Not clear |
| Sushil K Jain, Jeffrey Justin Margret, Marissa Lall. Positive association of acetylcholine esterase (AChE) with the neutrophil-to-lymphocyte ratio and HbA1c, and a negative association with hydrogen sulfide (H Free radical biology & medicine. 2023-10-22. PMID:37866755. |
positive association of acetylcholine esterase (ache) with the neutrophil-to-lymphocyte ratio and hba1c, and a negative association with hydrogen sulfide (h the incidence of alzheimer's disease (ad) is higher in people over the age of 65 and in african americans (aa). |
2023-10-22 |
2023-11-08 |
Not clear |
| Jia Liu, Wei Ha, Eshbakova Komila Alibekovna, Rui Ma, Yan-Ping Sh. Ruptured organosilica nanocapsules immobilized acetylcholinesterase coupled with MnO Nanoscale. 2023-10-20. PMID:37860933. |
ruptured organosilica nanocapsules immobilized acetylcholinesterase coupled with mno abnormal expression of acetylcholinesterase (ache) causes alzheimer's disease (ad). |
2023-10-20 |
2023-11-08 |
Not clear |
| Modesto de Candia, Alexander A Titov, Antonio Viayna, Larisa N Kulikova, Rosa Purgatorio, Brigida Piergiovanni, Mauro Niso, Marco Catto, Leonid G Voskressensky, F Javier Luque, Cosimo D Altomar. In-vitro and in-silico studies of annelated 1,4,7,8-tetrahydroazocine ester derivatives as nanomolar selective inhibitors of human butyrylcholinesterase. Chemico-biological interactions. 2023-10-15. PMID:37839515. |
based on previous finding showing 2,3,6,11-tetrahydro-1h-azocino[4,5-b]indole as suitable scaffold of novel inhibitors of acetylcholinesterase (ache), a main target of drugs for the treatment alzheimer disease and related dementias, herein we investigated diverse newly and previously synthesized β-enamino esters (and ketones) derivatives of 1,4,7,8-tetrahydroazocines (and some azonines) fused with benzene, 1h-indole, 4h-chromen-4-one and pyrimidin-4(3h)-one. |
2023-10-15 |
2023-11-08 |
human |
| Wenli Shi, Wenxin Han, Yijing Liao, Jiaqi Wen, Guowen Zhan. Inhibition mechanism of fisetin on acetylcholinesterase and its synergistic effect with galantamine. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. vol 305. 2023-09-28. PMID:37769468. |
the search for acetylcholinesterase (ache) inhibitors produced by natural sources is of great significance for the prevention and therapy of alzheimer's disease and has been widely concerned. |
2023-09-28 |
2023-10-07 |
Not clear |
| Shraddha Manish Gupta, Ashok Behera, Neetesh K Jain, Avanish Tripathi, Dinesh Rishipathak, Siddharth Singh, Nafees Ahemad, Meryem Erol, Devendra Kuma. Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment. RSC advances. vol 13. issue 38. 2023-09-06. PMID:37671344. |
leading pathological markers of alzheimer's disease (ad) include acetylcholinesterase (ache), butyrylcholinesterase (buche), amyloid beta (aβ) and reactive oxygen species (ros). |
2023-09-06 |
2023-10-07 |
human |
| Izaz Monir Kamal, Anamika Das, Sanjukta Datta, Kaninika Paul, Sasanka Chakrabarti, Saikat Chakrabarti, Paramita Bhattacharje. A Novel spice-antioxidant-based nano-vehicle as a putative green alternative of synthetic AChE inhibitor drugs. Journal of biomolecular structure & dynamics. 2023-08-28. PMID:37639732. |
the present treatment for alzheimer's disease (ad) involves well known synthetic acetylcholine esterase (ache) inhibitor drugs which besides having short duration of action also have deleterious impact on human health. |
2023-08-28 |
2023-09-07 |
human |
| Zhonghui Zhang, Zhichao Liu, Peicong Wu, Xinhua Guo, Xiao Luo, Youjun Yang, Jinquan Chen, Yang Tia. A High-Density Raman Photometry for Tracking and Quantifying of AchE Activity in The Brain of Freely Moving Animals with Network. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023-08-27. PMID:37635166. |
benefiting from the high-density photometry, it is found that the activity and distribution of ache varied in 24 brain regions, and the levels of ache activity in 24 brain regions of alzheimer's mice (ad) are lower than those of normal mice. |
2023-08-27 |
2023-09-07 |
mouse |
| Javier Avendaño-Godoy, Arnoldo Miranda, Sigrid Mennickent, Carolina Gómez-Gaet. Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation. Journal of pharmaceutical sciences. 2023-08-26. PMID:37595752. |
rivastigmine is an acetylcholinesterase (ache) and butyrylcholinesterase (bche) inhibitor drug approved by the us food and drug administration (fda) for the treatment of mild to moderate dementia of alzheimer's type. |
2023-08-26 |
2023-09-07 |
rat |
| Luciana R Tallini, Camila Rockenbach da Silva, Tatiana Jung, Elen de Oliveira Alves, Samira Leila Baldin, Miriam Apel, Luis F S M Timmers, Eduardo Pacheco Rico, Jaume Bastida, José Angelo S Zuanazz. Acetylcholinesterase Inhibition Activity of Life (Basel, Switzerland). vol 13. issue 8. 2023-08-26. PMID:37629578. |
galanthamine, the most relevant one, has been commercialized for the palliative treatment of alzheimer's disease symptoms since 2001 due to its potential as an acetylcholinesterase (ache) inhibitor. |
2023-08-26 |
2023-09-07 |
Not clear |